Group 1 - The core viewpoint of the news is that Chengda Pharmaceutical has shown mixed financial performance, with a notable increase in revenue but a significant decline in net profit [2] - As of November 6, 2023, Chengda Pharmaceutical's stock price increased by 0.93%, with a trading volume of 95.18 million yuan and a net financing outflow of 717,800 yuan [1] - The company's financing balance reached 247 million yuan, accounting for 5.09% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - For the period from January to September 2023, Chengda Pharmaceutical reported a revenue of 285 million yuan, representing a year-on-year growth of 16.95% [2] - The net profit attributable to the parent company was 16.77 million yuan, reflecting a year-on-year decrease of 58.47% [2] - The number of shareholders decreased by 8.58% to 12,700, while the average circulating shares per person increased by 36.16% to 8,577 shares [2] Group 3 - Since its A-share listing, Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends, with 89.62 million yuan paid out over the last three years [3]

Group 1 - The core point of the news is that Chengda Pharmaceutical (301201.SZ) has seen a significant decline in its stock price, closing at 31.10 yuan with a drop of 6.13% [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext on January 20, 2022, with an initial public offering (IPO) of 24,174,035 shares at a price of 72.69 yuan per share [1] - The stock reached its highest point at 188.00 yuan on the first day of trading but is currently in a state of decline [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising amount exceeded the originally planned amount by 1,108.17 million yuan, which was initially set at 513.28 million yuan for various projects [1] - The total issuance costs for the IPO were 135.76 million yuan, including underwriting fees of 117.93 million yuan [1] Group 3 - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 6 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [2]

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201.SZ) experienced a stock price decline of 6.13%, closing at 31.10 yuan [1] - Haitong Securities analyst Hua Ting published a report on November 1, 2023, recommending an "overweight" rating for Chengda Pharmaceutical, focusing on its transformation towards cell and gene therapy [1]

Core Viewpoint - Chengda Pharmaceutical is a leading domestic pharmaceutical company focusing on key pharmaceutical intermediates CDMO services and L-carnitine series products, with strong R&D capabilities [1] Group 1: Business Performance - In Q3 2025, Chengda Pharmaceutical reported revenue of 285 million yuan, ranking 26th out of 29 in the industry, significantly lower than the top company WuXi AppTec at 32.857 billion yuan and second-ranked Kanglong Chemical at 10.086 billion yuan [2] - The net profit for Q3 2025 was 16.7931 million yuan, ranking 22nd out of 29, with a notable gap compared to WuXi AppTec's 12.206 billion yuan and Tigermed's 1.092 billion yuan [2] Group 2: Financial Ratios - Chengda Pharmaceutical's debt-to-asset ratio in Q3 2025 was 9.98%, up from 6.78% year-on-year, significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 45.39%, an increase from 43.54% year-on-year, surpassing the industry average of 37.70%, reflecting strong profitability [3] Group 3: Executive Compensation - The chairman, Ge Jianli, received a salary of 602,700 yuan in 2024, a decrease of 374,200 yuan from 2023 [4] - The general manager, Lu Gang, earned 668,800 yuan in 2024, down 223,900 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.58% to 12,700, while the average number of circulating A-shares held per account increased by 36.16% to 8,577.86 [5]

Core Viewpoint - Chengda Pharmaceutical's stock performance shows a slight increase, with significant financing activity indicating investor interest despite a decline in net profit year-over-year [1][2]. Financing Activity - On October 28, Chengda Pharmaceutical's stock rose by 0.46%, with a trading volume of 103 million yuan. The financing buy-in amounted to 10.23 million yuan, while financing repayment was 8.51 million yuan, resulting in a net financing buy-in of 1.72 million yuan [1]. - As of October 28, the total financing and securities lending balance for Chengda Pharmaceutical was 254 million yuan, representing 4.99% of its market capitalization. This financing balance is above the 90th percentile of the past year, indicating a high level of investor engagement [1]. - In terms of securities lending, there were no shares repaid or sold on October 28, with a total securities lending balance of 0, which is below the 50th percentile of the past year, indicating a low level of short selling activity [1]. Financial Performance - For the period from January to September 2025, Chengda Pharmaceutical reported a revenue of 285 million yuan, reflecting a year-over-year growth of 16.95%. However, the net profit attributable to shareholders decreased by 58.47% to 16.77 million yuan [2]. - As of September 30, the number of shareholders for Chengda Pharmaceutical was 12,700, a decrease of 8.58% from the previous period. The average number of circulating shares per shareholder increased by 36.16% to 8,577 shares [2]. Dividend Distribution - Since its A-share listing, Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends, with 89.62 million yuan distributed over the past three years [3].

Core Insights - The report emphasizes the significant role of phosphoramidite monomers in the small nucleic acid industry chain, highlighting their impact on the development of small nucleic acid drugs, which are considered promising candidates for treating various diseases due to their unique molecular structures and therapeutic mechanisms [1][6][10] - The report predicts robust growth in the demand for phosphoramidite monomers, with multinational pharmaceutical companies likely to benefit from this trend, as the global nucleotide market is projected to reach USD 730 million in 2023, with China being the largest production market [10][11] Section Summaries Phosphoramidite Monomer's Role - Phosphoramidite monomers are crucial raw materials for synthesizing small nucleic acid drugs, enhancing their stability and biological activity, and driving innovation in drug development [6][9] - The solid-phase phosphoramidite method is the mainstream technique for synthesizing oligonucleotides, which are a major cost component in nucleic acid drug production [9] Market Dynamics - The report notes that 90% of global nucleotides are used for nucleic acid drug production, with only about 10% allocated to health foods and agriculture [10] - The small nucleic acid drug market is primarily dependent on major multinational pharmaceutical companies, indicating potential benefits for companies within their supply chains [11] Investment Recommendations - The report suggests focusing on innovative drug companies such as Furuya Co., OncoOne, and others, as well as raw material suppliers like WuXi AppTec and others, indicating a diverse range of investment opportunities in the sector [10]

Core Viewpoint - Chengda Pharmaceutical announced the nomination of five candidates for non-independent directors and three candidates for independent directors for its sixth board of directors [1] Group 1 - The company’s board of directors has proposed the nomination of five non-independent director candidates: Ge Jianli, Lu Gang, Huang Honglin, Lu Jin, and Li Wenjuan [1] - The company has also nominated three independent director candidates: Hu Yongzhou, Jiang Lin, and Zhou Junming [1]

Group 1 - The core point of the article is that Chengda Pharmaceutical (SZ 301201) held its 14th meeting of the 5th Board of Directors on October 24, 2025, where it reviewed the proposal to amend the "Audit Committee Annual Work Regulations" [1] - For the year 2024, Chengda Pharmaceutical's revenue composition is as follows: 55.67% from pharmaceutical manufacturing, 43.0% from food manufacturing, 0.69% from other businesses, and 0.65% from trade-related income [1] - As of the time of reporting, Chengda Pharmaceutical has a market capitalization of 5.1 billion yuan [1]

诚达药业股份有限公司 信息披露管理制度 第一章 总则 第一条 为规范诚达药业股份有限公司（下称"公司"）及相关信息披露义 务人的信息披露行为，确保公司信息披露内容的真实、准确、完整，切实维护公 司、股东及投资者的合法权益，根据《中华人民共和国公司法》（以下简称《公 司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公司信 息披露管理办法》（以下简称《管理办法》）、《上市公司信息披露暂缓与豁免 管理规定》《深圳证券交易所创业板股票上市规则》（以下简称《上市规则》）、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （下称《自律监管指引第 2 号》）、《深圳证券交易所上市公司自律监管指引第 5 号——信息披露事务管理》等法律、法规及《诚达药业股份有限公司章程》（以 下简称《公司章程》）的规定，并结合公司实际情况，制定本制度。 第二条 本制度所称"信息"是指所有可能对公司股票及其衍生品种交易价 格或者投资者决策产生较大影响而投资者尚未得知的信息或事项以及证券监管 部门要求披露的信息。 本制度所称"披露"是指公司及相关信息披露义务人按法律、行政法规、部 门规章、规范性文件、证 ...

诚达药业股份有限公司 重大信息内部报告制度 第一章 总则 第一条 为加强诚达药业股份有限公司（以下称"公司"）重大信息内部报告 工作，确保公司依法、及时地归集重大信息，真实、准确、完整地履行信息披露义 务，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《上市公司信息披露管理办法》《深圳证券交易所股票上市规则》、《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及其他有关 法律、法规和规范性文件和《诚达药业股份有限公司章程》（以下称《公司章 程》）《信息披露管理制度》的规定，特制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公司 股票及其衍生品种交易价格或者投资决策产生较大影响的情形或事件时，负有报告 义务的责任人按照本制度规定，应当及时将相关信息向公司董事会和董事会秘书进 行报告。 本制度适用于公司、分公司、控股子公司、参股公司。 第三条 下列人员为制度所称"信息报告义务人"： （一）公司董事、高级管理人员，各部门负责人； （二）公司控股子公司负责人、分支机构负责人、财务部门负责人及指定联络 人； （三）公司派驻参股公司的董事 ...